Office of Translational Research and Residency Programs, Tabula Rasa HealthCare, 228 Strawbridge Drive, Moorestown, NJ, 08057, USA.
Precision Pharmacotherapy Research & Development Institute, Tabula Rasa HealthCare, Lake Nona, FL, USA.
BMC Psychiatry. 2022 Jan 20;22(1):46. doi: 10.1186/s12888-021-03659-4.
Response to antidepressant therapy is highly variable among individuals. Pharmacogenomic (PGx) testing presents an opportunity to guide drug selection while optimizing therapy outcomes and/or decreasing the risk for toxicity.
A patient with multiple comorbidities, including severe major depressive disorder (MDD), experienced adverse drug events and undesirable response to multiple antidepressant medications (i.e., bupropion, escitalopram, and venlafaxine). A clinical pharmacist assessed significant drug-gene, drug-drug, and drug-drug-gene interactions as well as other clinical factors to provide recommendations for antidepressant therapy optimization.
This case highlights the importance of PGx testing and the key role of pharmacists in identifying and mitigating drug-related problems and optimizing drug therapy in patients with MDD.
抗抑郁治疗的反应在个体之间差异很大。药物基因组学（PGx）检测提供了一个机会，可以在优化治疗效果和/或降低毒性风险的同时指导药物选择。
一名患者患有多种合并症，包括严重的重度抑郁症（MDD），经历了药物不良反应和对多种抗抑郁药物（如安非他酮、依地普仑和文拉法辛）的不良反应。临床药师评估了重要的药物-基因、药物-药物和药物-药物-基因相互作用以及其他临床因素，为优化抗抑郁治疗提供了建议。
本病例强调了 PGx 检测的重要性以及药师在确定和减轻与药物相关的问题以及优化 MDD 患者药物治疗方面的关键作用。
